Epirus grabs $36 mln Series B funds and merges with Zalicus
Epirus Biopharmaceuticals said Wednesday that it has secured $36 million in Series B funding. Livzon Mabpharm led the round with participation from other investors that include Adage Capital, Greenwoods Investment, Gibralt US, Monashee Capital Partners, TPG Biotech, Montreux Equity Partners and 5AM Ventures. Also, Epirus will merge with Zalicus. No financial terms were disclosed. The merged entity will be led by Amit Munshi as president and CEO. Based in Boston, Epirus is a biopharmaceutical firm focused on biosimilar monoclonal antibodies while Zalicus specializes in developing new treatments for patients suffering from pain and inflammation.
16 April 2014•5 mins read
